US EditionHepion Pharmaceuticals, New Day Diagnostics execute binding letter of intent
Summary by Teknovation
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Hepion Pharmaceuticals, New Day Diagnostics execute binding letter of intent
Hepion Pharmaceuticals Inc., a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis, hepatocellular carcinoma, and other chronic liver diseases, has announced that it has entered into a binding letter of intent (LOI) with Knoxville-headquartered New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pyl…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
